Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

BLUE Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies bluebird bio, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

ACCESSWIRE IA February 17, 2021

BLUEBIRD BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against bluebird bio, Inc.

GlobeNewswire February 16, 2021

INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA February 16, 2021

LAWSUIT FILED: bluebird bio, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP

GlobeNewswire February 16, 2021

BLUE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 13, 2021 in the Class Action Filed on Behalf of bluebird bio, Inc. Limited Shareholders

Newsfile February 16, 2021

Portnoy Law: Lawsuit Filed On Behalf of Bluebird Bio Inc. Investors

GlobeNewswire February 16, 2021

SHAREHOLDER ALERT: Holzer & Holzer Announces that a Class Action Was Filed on Behalf of bluebird bio Investors and Encourages Investors With Significant Losses to Contact the Firm

Newsfile February 16, 2021

bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)

Business Wire February 16, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in bluebird bio, Inc. of Class Action Lawsuit and Upcoming Deadline - BLUE

Newsfile February 15, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of bluebird bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 13, 2021 - BLUE

Newsfile February 15, 2021

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (BLUE)

GlobeNewswire February 15, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire February 15, 2021

BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline - BLUE

Business Wire February 15, 2021

Have You Invested In bluebird bio, Inc.? - Class Action Lawsuit Filed On Behalf Of BLUE Investors - Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.

GlobeNewswire February 15, 2021

BLUE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies bluebird bio, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

ACCESSWIRE IA February 15, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in bluebird bio, Inc. of Class Action Lawsuit and Upcoming Deadline - BLUE

ACCESSWIRE IA February 13, 2021

BLUEBIRD BIO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. and Encourages Investors to Contact the Firm

Business Wire February 12, 2021

Pomerantz Law Firm Announces the Filing of a Class Action against bluebird bio, Inc. and Certain Officers - BLUE

PR Newswire February 12, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of bluebird bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 13, 2021 - BLUE

Newsfile February 12, 2021

LAWSUIT FILED: bluebird bio, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP

ACCESSWIRE IA February 12, 2021